Diazyme has received an FDA emergency use authorization (EUA) for the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA test. The Diazyme IgM covid-19 antibody test runs on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer. “Diazyme continues to serve during the public health emergency with innovative products in covid-19 serology (antibody) testing,” says Chong Yuan, PhD, managing director of Diazyme Laboratories. “The IgM test is typically used together with the IgG test for a more complete serology profile. The Diazyme DZ-Lite SARS-CoV-2 IgM test is highly sensitive and specific and does not cross-react when tested with an extensive list of interferents, including no cross reactivity to the common HKU1, OC43, NL63, 229E coronavirus strains. Recent independent performance studies in peer-reviewed journals cite excellent results with Diazyme serology tests.” For more information, visit Diazyme Laboratories.